Results of Liver Transplantation: Analysis of 140 Cases at a Single Center

Malek-Hosseini, S.A.; Mehdizadeh, Alireza; Salahi, H; Saberi-Firouzi, Mehdi; Lankarani, Kamran Bagheri; Bahador, Abbas; Imanieh, Mohammad Hadi; Nikeghbalian, S; Lahsaee, M; Khosravi, Mohammad Bagher; Arasteh, M. M.; Bagheri, Mohamad; Geramizadeh, Bita; Razmkon, Ali; Tabei, S. Z.

doi:10.1016/j.transproceed.2005.07.005

Cited by 8 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depending on the method of diagnosis and the stage of cirrhosis, the prevalence of PVT in cirrhotic patients ranges from < 0.6% in compensated cirrhosis ( 3 ) to 28% in liver transplant candidates ( 4 - 7 ). PVT may make liver transplantation more technically difficult ( 8 , 9 ).…”

Section: Introductionmentioning

confidence: 99%

Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran

et al. 2015

View full text Add to dashboard Cite

Background:Portal vein thrombosis is a fairly common and potentially life-threatening complication in patients with liver cirrhosis. The risk factors for portal vein thrombosis in these patients are still not fully understood.Objectives:This study aimed to investigate the associations between various risk factors in cirrhotic patients and the development of portal vein thrombosis.Patients and Methods:In this case-control study performed at the Shiraz organ transplantation center, Iran, we studied 219 patients (> 18 years old) with liver cirrhosis, who were awaiting liver transplants in our unit, from November 2010 to May 2011. The patients were evaluated by history, physical examination, and laboratory tests, including factor V Leiden, prothrombin gene mutation, Janus Kinase 2 (JAK2) mutation, and serum levels of protein C, protein S, antithrombin III, homocysteine, factor VIII, and anticardiolipin antibodies.Results:There was no statistically significant difference in the assessed hypercoagulable states between patients with or without portal vein thrombosis. A history of previous variceal bleeding with subsequent endoscopic treatment in patients with portal vein thrombosis was significantly higher than in those without it (P = 0.013, OR: 2.526, 95% CI: 1.200 - 5.317).Conclusions:In our population of cirrhotic patients, treatment of variceal bleeding predisposed the patients to portal vein thrombosis, but hypercoagulable disorders by themselves were not associated with portal vein thrombosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Shiraz Organ Transplant Center in southern Iran began to perform liver transplantation since 1993, Potential recipients are placed on a waiting list based on the established standard indications for liver transplantation (62). Patients with decompensated cirrhosis with any level of HBV DNA are advised to receive antiviral therapy; in most cases with tenofovir 300 mg per day The intention is to suppress HBV DNA to undetectable levels (50 IU/ml).…”

Section: Iranian Experience Regarding Liver Transplantation In Pamentioning

confidence: 99%

Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran

Alavian¹,

Lankarani

Rizzetto

et al. 2012

Hepat Mon

View full text Add to dashboard Cite

Hepatitis B infection is the main cause of liver related mortality in many countries including Iran. Liver transplantation in cirrhosis due to HBV infection before 1990 was an absolute contraindication. Recurrent infection was a significant event in post liver transplant setting and resulted in increased risk of graft failure and death except successful transplanted individuals. Advances in antiviral prophylaxis have now made graft reinfection majority patients as a rare event. Graft and patient survival have been improved significantly during the past two decades, and consequences of transplantation for hepatitis B virus are now superior to those achieved for most other indications. This has encouraged many centers including the major liver transplantation center of Iran, in Shiraz, to provide liver transplantation to more patients with HBV related end stage liver disease. Management of these patients begins before transplantation along with special care after transplantation. There are some myths and doubts in the management of these patients and one should always balance the cost and efficiency. One of the major concerns is the high economic and social cost of recurrence and all possible efforts should be performed to avoid the ominous consequences of reinfection. Having a clear scientific grasp on the management of HBV cirrhosis before and after liver transplantation, options and protocols, and changing the concept which HBV infected are contraindicated ones for liver transplantation, and future hopes in increasing patients survival after liver transplantation using the new nucleosides analogues and availability of hepatitis B immunoglobulin in the transplantation setting. This scientific report paper outlines the insights communicated at the HBV and liver transplantation symposium during 10th Congress of the Iranian Society for Organ Transplantation, May 2011, Shiraz, Iran.

show abstract

“…In most developing countries including India, orthotopic liver transplantation (OLT) has recently begun making headway [8,9] and has gathered momentum. The availability of reliable data on the different etiologic types of end-stage CLD and their prevalence in a community as well as on adequate criteria for their diagnosis is essential for planning effective healthcare programs for these.…”

Section: Introductionmentioning

confidence: 99%

Etiologic types of end-stage chronic liver disease in adults

Nayak¹,

Jain²,

Vasdev³

et al. 2012

European Journal of Gastroenterology & Hepatology

View full text Add to dashboard Cite

The etiology of end-stage CLD in adults of our region has changed over time. HCV, more than HBV, is now the major cause of both CLD and HCC; alcohol-related CLD has increased significantly and several cases of cirrhosis clinically considered as cryptogenic, some of them with HCC, evolve from NAFLD. A proportion of cryptogenic cirrhosis cases that require LT are constituted by the noncirrhotic disease noncirrhotic portal fibrosis.

show abstract

Results of Liver Transplantation: Analysis of 140 Cases at a Single Center

Cited by 8 publications

References 7 publications

Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran

Risk Factors for Portal Vein Thrombosis in Patients With Cirrhosis Awaiting Liver Transplantation in Shiraz, Iran

Management of Hepatitis B Virus Infection in Liver Transplantation Setting; The Rising Concerns and Growing Hopes, Report From 10th Congress of the Iranian Society for Organ Transplantation, 2011, Shiraz, Iran

Etiologic types of end-stage chronic liver disease in adults

Contact Info

Product

Resources

About